#1 Clinical Trials Search in Europe

Crovalimab

Crovalimab is an investigational drug being studied in clinical trials for the treatment of several rare blood disorders, including paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), sickle cell disease (SCD), and Guillain-Barré syndrome (GBS). These trials aim to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of crovalimab compared to existing treatments or placebo in patients with these conditions.

Table of Contents

What is Crovalimab?

Crovalimab is a new medication being developed to treat various blood disorders and other conditions. It is currently undergoing clinical trials to evaluate its safety and effectiveness. Crovalimab belongs to a class of drugs called complement inhibitors, which work by targeting a specific part of the immune system[1].

What Conditions Does Crovalimab Treat?

Crovalimab is being studied for the treatment of several conditions, including:

  • Paroxysmal Nocturnal Hemoglobinuria (PNH): A rare blood disorder where red blood cells break down faster than normal, leading to anemia and other complications[2].
  • Atypical Hemolytic Uremic Syndrome (aHUS): A rare condition that causes abnormal blood clots to form in small blood vessels throughout the body, leading to kidney problems and other issues[3].
  • Sickle Cell Disease (SCD): An inherited blood disorder that affects the shape of red blood cells, causing pain and other complications[4].
  • Guillain-Barré Syndrome (GBS): A rare neurological disorder where the body’s immune system mistakenly attacks the nerves, causing muscle weakness and sometimes paralysis[5].

How Does Crovalimab Work?

Crovalimab works by targeting a specific protein in the body called complement component 5 (C5). This protein is part of the complement system, which is a group of proteins that help the immune system fight infections. In some conditions, like PNH and aHUS, the complement system becomes overactive and starts attacking healthy cells. By blocking C5, crovalimab helps to prevent this harmful activity and reduce symptoms of these diseases[6].

How is Crovalimab Administered?

Crovalimab is given in two main ways:

  1. Intravenous (IV) infusion: This is usually done for the initial dose, where the medication is given directly into a vein.
  2. Subcutaneous (SC) injection: After the initial dose, patients may receive crovalimab through injections under the skin.

The dosing schedule varies depending on the condition being treated and the patient’s body weight. Typically, patients receive a loading dose followed by maintenance doses every 1-4 weeks[1][2].

Ongoing Clinical Trials

Crovalimab is currently being studied in several clinical trials for different conditions:

  • Phase III trials for PNH in adults and adolescents[2][1]
  • Phase III trials for aHUS in adults, adolescents, and children[3][7]
  • Phase II trials for sickle cell disease[4]
  • Phase III trial for Guillain-Barré Syndrome[5]

These trials are designed to evaluate the safety, effectiveness, and optimal dosing of crovalimab for each condition.

Efficacy of Crovalimab

Early results from clinical trials suggest that crovalimab may be effective in treating various blood disorders. For example:

  • In PNH trials, crovalimab has shown promise in controlling hemolysis (the breakdown of red blood cells) and reducing the need for blood transfusions[2].
  • For aHUS, studies are looking at how well crovalimab improves kidney function and controls the disease[3].
  • In sickle cell disease, researchers are investigating whether crovalimab can reduce the frequency and severity of pain crises[4].

Safety and Side Effects

As with any new medication, researchers are closely monitoring the safety of crovalimab. Common side effects being studied include:

  • Injection site reactions (redness, pain, or swelling where the medication is injected)
  • Infusion-related reactions (symptoms that occur during or shortly after receiving an IV dose)
  • Infections (including the risk of meningococcal infections, which can be serious)

Patients in clinical trials are carefully monitored for these and other potential side effects[1][8].

Future Prospects for Crovalimab

If the ongoing clinical trials continue to show positive results, crovalimab could become an important treatment option for patients with PNH, aHUS, sickle cell disease, and potentially other conditions. Some potential advantages of crovalimab being studied include:

  • Less frequent dosing compared to some existing treatments
  • The ability to self-administer at home (for subcutaneous injections)
  • Potential improvements in quality of life for patients with these chronic conditions

As research continues, more information will become available about the long-term effectiveness and safety of crovalimab[6].

Aspect Details
Drug Name Crovalimab
Conditions Studied Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS), Sickle Cell Disease (SCD), Guillain-Barré Syndrome (GBS)
Administration Intravenous (IV) infusion and subcutaneous (SC) injections
Primary Outcomes Efficacy (e.g., hemolysis control, transfusion avoidance), Safety (adverse events), Pharmacological measures
Study Designs Phase I/II and Phase III trials, including randomized, placebo-controlled, and open-label studies
Comparators Placebo, Eculizumab (for PNH studies)
Key Measurements Lactate Dehydrogenase (LDH) levels, Complement activity, Quality of life scores, Transfusion requirements
Safety Monitoring Adverse events, Injection-site reactions, Infusion-related reactions, Anti-drug antibodies
Study Durations 24-25 weeks for primary treatment, with some studies having longer follow-up or extension phases

FAQ

  • What is crovalimab? Crovalimab is an investigational drug being studied for the treatment of several rare blood disorders. It is a complement inhibitor that targets the C5 protein in the complement system, which is part of the immune system.
  • What conditions is crovalimab being studied for? Crovalimab is being investigated in clinical trials for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), sickle cell disease (SCD), and Guillain-Barré syndrome (GBS).
  • How is crovalimab administered? Crovalimab is typically administered through a combination of intravenous (IV) infusion and subcutaneous (SC) injections. The dosing schedule and amounts vary depending on the specific trial and condition being studied.
  • What are the primary outcomes being measured in these trials? The primary outcomes vary by trial but generally include measures of efficacy (such as hemolysis control, transfusion avoidance, or functional improvement), safety (adverse events), and pharmacological measures (drug concentrations and effects on complement activity).
  • How long do these clinical trials last? The duration of the trials varies, with some lasting up to 24-25 weeks for the primary treatment period, while others have longer follow-up periods or extension phases that can last several years.

Ongoing Clinical Trials on Crovalimab

  • Study on the Effectiveness and Safety of Crovalimab for Children with Atypical Hemolytic Uremic Syndrome (aHUS)

    Not recruiting

    1 1 1
    Investigated drugs:
    Belgium France Hungary Italy Poland Spain

  • Study on the Safety and Effectiveness of Crovalimab for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

    Not recruiting

    1
    Investigated drugs:
    France Germany Hungary Italy

  • Study on the Effects and Safety of Crovalimab for Adults and Adolescents with Atypical Hemolytic Uremic Syndrome (aHUS)

    Not recruiting

    1 1 1
    Investigated drugs:
    Belgium France Germany Hungary Italy Poland +1

  • Study Comparing Crovalimab and Eculizumab for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently on Complement Inhibitors

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia Estonia France Germany Greece +7

  • Study on the Effectiveness and Safety of Crovalimab vs. Eculizumab for Adults and Adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Treated with Complement Inhibitors

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Lithuania The Netherlands Poland Portugal +3

  • Study on the Safety and Effects of Crovalimab for Treating Vaso-Occlusive Episodes in Sickle Cell Disease Patients

    Not recruiting

    1
    Investigated diseases:
    Investigated drugs:
    France Italy The Netherlands Spain

Glossary

  • Paroxysmal Nocturnal Hemoglobinuria (PNH): A rare blood disorder characterized by the destruction of red blood cells, blood clots, and impaired bone marrow function.
  • Atypical Hemolytic Uremic Syndrome (aHUS): A rare disease that causes abnormal blood clots to form in small blood vessels in the kidneys, which can lead to kidney failure.
  • Sickle Cell Disease (SCD): A group of inherited red blood cell disorders where red blood cells become hard and sticky, taking on a C-shape (like a sickle).
  • Guillain-Barré Syndrome (GBS): A rare neurological disorder in which the body's immune system mistakenly attacks part of its peripheral nervous system.
  • Complement System: A part of the immune system that enhances the ability of antibodies and phagocytic cells to clear microbes and damaged cells from an organism.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and excreted by the body.
  • Pharmacodynamics: The study of the biochemical and physiological effects of drugs on the body and the mechanisms of drug action.
  • Hemolysis: The destruction of red blood cells, which leads to the release of hemoglobin into the bloodstream.
  • Lactate Dehydrogenase (LDH): An enzyme found in nearly all living cells that is released into the bloodstream when cells are damaged or destroyed.
  • Anti-Drug Antibodies (ADAs): Antibodies that develop in response to a therapeutic drug, which can potentially reduce the drug's effectiveness or cause adverse reactions.

References

  1. https://clinicaltrials.gov/study/NCT04434092
  2. https://clinicaltrials.gov/study/NCT04654468
  3. https://clinicaltrials.gov/study/NCT04958265
  4. https://clinicaltrials.gov/study/NCT05075824
  5. https://clinicaltrials.gov/study/NCT05494619
  6. https://clinicaltrials.gov/study/NCT03157635
  7. https://clinicaltrials.gov/study/NCT04861259
  8. https://clinicaltrials.gov/study/NCT04432584